-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-514014-13-00
9
2020-09-02
female and male adult patients with acute myeloid leukemia
-
2024-514962-38-00
1
2020-08-25
Solid Tumors
-
2024-515114-41-00
7
2020-08-10
Solid tumors
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2023-509846-36-00
9
2020-05-29
Advanced Solid Tumors
-
2024-510841-32-00
1
2020-05-27
Advanced or metastatic carcinomas after previous immune checkpoint blo
-
2023-506914-32-00
4
2020-05-05
Pan tumor
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2024-512606-25-00
7
2019-12-20
Advanced Solid Tumors
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2024-512104-19-00
6
2019-11-19
Irritable Bowel Syndrome
-
2023-509343-27-00
11
2019-10-28
C3 Glomerulopathy or idiopathic immune-complex membranoproliferative g
-
2023-508455-38-00
5
2019-09-12
Hyperkalaemia
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-514409-78-01
9
2019-07-26
relapsed / refractory or progressive high risk malignant disease
-
2023-508302-24-00
4
2019-05-07
Locally Advanced/Metastatic Urothelial Cancer
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2024-516832-82-00
9
2018-08-27
Accute lymphoblastic leukemia recurrent, Non-Hodgkin´s lymphoma NOS re
-
2024-514238-19-00
4
2018-03-28
Subjects with advanced solid tumour
-
2023-509318-13-00
6
2018-01-15
Multiple indications
-
2024-511988-29-01
3
2017-11-08
Glioblastoma
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2025-521067-13-00
5
2026-04-24
Atherosclerotic Cardiovascular Disease (ASCVD)